Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVAC-1 (University of Saskatchewan)
- Development stage
- Unknown
- Lead developer
- University of Saskatchewan
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
COVAC-1 is a protein subunit COVID-19 vaccine candidate developed by the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan. The vaccine contains a purified S1 portion of the SARS-CoV-2 spike protein, which is the primary component responsible for viral attachment to host cells. To enhance the immune response, COVAC-1 is formulated with TriAdj, a triple-component adjuvant consisting of a toll-like receptor agonist (polyI:C), an immunostimulatory host defense protein (HDP IDR-1002), and a polyphosphazene carrier system (PCEP). Developed based on expertise with SARS and MERS, the vaccine aims to stimulate the production of neutralizing antibodies to prevent or reduce the severity of COVID-19. It has been evaluated in Phase 1 clinical trials for safety and immunogenicity in healthy adults.
- Other names
- VIDO COVID-19 vaccineUniversity of Saskatchewan COVID-19 vaccine
02
Targets
TLR3 (Toll-like receptor 3)SARS-CoV-2 spike
Beyond the preview
Go deeper on COVAC-1 (University of Saskatchewan).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVAC-1 (University of Saskatchewan).